Study Title and Description
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Key Questions Addressed
|3||In adult renal transplants, how do immunosuppressive regimens designed to reduce or eliminate exposure to CNI toxicity compare with each other and with full-dose CNI regimens for health outcomes? AND How does the type of induction agent (including when no induction is used) and the use of concurrent immunosuppressive agents affect outcomes of regimens that reduce or eliminate CNI exposure?|
Primary Publication Information
|Title||A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).|
|Author||Vincenti F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., Massari P., Mondragon-Ramirez GA., Agarwal M., Di Russo G., Lin CS., Garg P., Larsen CP.|
|Country||Kidney Transplant Service, University of California-San Francisco, San Francisco, CA, USA. Flavio.Vincenti@ucsfmedctr.org|
Pubmed ID: 20415897
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Comparative Effectiveness of Regimens
Results & Comparisons
No Results found.